Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07615166 · ClinicalTrials.gov registry record
Low-Density Lipoprotein Cholesterol Reduction With Alirocumab 150 mg Versus Inclisiran in Individuals Initiating Therapy in Routine Clinical Practice
A clinical trial, sponsored by Sanofi.
- Completed
- Registry status
- 996
- Enrollment target
NCT07615166: Completed study, sponsored by Sanofi.
NCT07615166 is a clinical trial that has completed, run by Sanofi. The registered enrollment target is 996 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07615166 has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- 996 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate LDL-C reduction over time among individuals initiating alirocumab 150 mg compared with inclisiran in routine clinical practice. The study will leverage observational data reflective of routine care and apply contemporary methods in target trial emulation and causal inference to estimate comparative treatment effects.
Interventions
- DRUG Inclisiran
- DRUG Alirocumab 150 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 996 participants |
| Start Date | 2025-05-22 |
| Est. Completion | 2026-06-30 |
What the finished NCT07615166 record still lists
NCT07615166 is an observational study that tracks outcomes without assigning an intervention. The registered 996 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which Inclisiran is the first listed.
NCT07615166 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07615166 about?
NCT07615166 is a clinical study titled "Low-Density Lipoprotein Cholesterol Reduction With Alirocumab 150 mg Versus Inclisiran in Individuals Initiating Therapy in Routine Clinical Practice". The objective of this study is to evaluate LDL-C reduction over time among individuals initiating alirocumab 150 mg compared with inclisiran in routine clinical practice. The study will leverage observational data reflective of routine care and apply contemporary methods in target trial emulation an...
What is the current status of trial NCT07615166?
This trial is currently completed. The enrollment target is 996 participants. The study started on 2025-05-22. Estimated completion is 2026-06-30.
What interventions are being tested in trial NCT07615166?
The interventions under investigation include: Inclisiran (DRUG), Alirocumab 150 mg (DRUG).
Who is sponsoring clinical trial NCT07615166?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07005024 · 996 participants · Phase 3
DOAC - Dosing Options in AntiCoagulation Prophylaxis
- NCT05437575 · 994 participants · Phase 3
Prehospital Analgesia INtervention Trial (PAIN)
- NCT06671704 · 994 participants · NA
GC-PRO Intervention
- NCT02986048 · 999 participants
Proton Therapy Patient Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI